Avidity Biosciences, Inc.
Avidity Biosciences, Inc. (RNAM): 12 pipeline candidates · ~14 mo cash runway · 12 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
14.3 months
D/E 0.16 · 0% dilution
Lead: Phase 3
12 candidates
N/A
0 buys · 18 sells (180d)
A transparent, data-derived signal for Avidity Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$11.2B
Cash
$385.3M
Quarterly Burn
$169.8M
Runway
14.3 mo
Revenue
$860K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| aoc 1001 | Phase 1/Phase 2 |
| aoc 1020 | Phase 1/Phase 2 |
| aoc 1044 | Phase 1/Phase 2 |
| AOC 1072 | Phase 3 |
| AOC 1086 | Phase 3 |
| aoc-1020 | Phase 3 |
| del-desiran | Phase 3 |
| Delpacibart braxlosiran (del-brax) | Phase 3 |
| Delpacibart etedesiran (del-desiran) | Phase 3 |
| delpacibart zotadirsen | Phase 3 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Avidity Biosciences, Inc.'s pipeline?
Avidity Biosciences, Inc. (RNAM) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Avidity Biosciences, Inc.'s lead drug candidate?
Avidity Biosciences, Inc.'s most advanced tracked candidate is aoc 1001 (Phase 1/Phase 2) for DM1.
What is Avidity Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Avidity Biosciences, Inc. has approximately 14.3 months of cash runway.
What is Avidity Biosciences, Inc.'s market capitalization?
Avidity Biosciences, Inc.'s market capitalization is approximately $11.2B.
Who is the CEO of Avidity Biosciences, Inc.?
Ms. Sarah Boyce is the chief executive officer of Avidity Biosciences, Inc. (RNAM).
Get the full picture on Avidity Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.